Lataa...
Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma
Sorafenib is the first-line treatment for patients with advanced unresectable hepatocellular carcinoma (HCC); however, only a small number of patients benefit from sorafenib, and many develop sorafenib resistance (SR) and severe side effects. To identify biomarkers for SR, we systematically analyzed...
Tallennettuna:
| Julkaisussa: | Aging (Albany NY) |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7906139/ https://ncbi.nlm.nih.gov/pubmed/33495404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.202365 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|